<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Lerch M</dc:creator>
  <dc:creator>Pichler WJ</dc:creator>
  <dc:date>2004</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">PURPOSE OF REVIEW
Drug-induced exanthems are the most common manifestations of drug hypersensitivity and are observed in as much as 2-3% of hospitalized patients. Here we summarize new concepts of the immune mechanisms underlying various forms of drug-induced exanthems.


RECENT FINDINGS
Alpha-betaTCR+, CD4 and CD8+ T cells are involved in different drug hypersensitivity reactions. Their function determines the clinical picture. In maculopapular, bullous and pustular exanthems cytotoxic T cells are involved, while a high IL-5 and eotaxin production by tissue cells is frequently found in maculopapular and occasionally in bullous and in pustular exanthems. High IL-8 (CXCL-8) and granulocyte-macrophage colony stimulating factor production by T cells is a hallmark of pustular drug exanthems. In the most severe and potentially life-threatening forms of exanthems (Stevens-Johnson syndrome/toxic epidermal necrolysis) cytotoxic CD8+ T cells with natural killer cell markers can be found in the blister fluid.


SUMMARY
These findings are the basis for a new subclassification of delayed, type IV hypersensitivity reactions into type IVa (T helper type 1 cells, e.g. tuberculin reaction and contact dermatitis), IVb (T helper type 2 cells, maculopapular exanthem with eosinophilia), IVc (cytotoxic T cells, contact dermatitis, maculopapular and bullous exanthem), and IVd reactions (CXCL-8/granulocyte-macrophage colony stimulating factor-producing T cells and neutrophil attraction, pustular exanthems), by which, in most reactions, various mechanisms occur together but one reaction dominates the clinical picture.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/1028</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/00130832-200410000-00013</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/15349041</dc:relation>
  <dc:source>Current opinion in allergy and clinical immunology. - 2004</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Drug Eruptions</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Exanthema</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Time Factors</dc:subject>
  <dc:title xmlns:ns5="xml" ns5:lang="en">The immunological and clinical spectrum of delayed drug-induced exanthems.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
